Short answer
CRISPR Therapeutics AG (CRSP) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $889,000 (up 47.7% year over year) with net income of −$106M.
Q3 2025 key financials · XBRL
- Revenue
- $889,000
- +47.7% YoY · −0.3% QoQ
- Net income
- −$106M
- −23.9% YoY · +49.0% QoQ
- Operating margin
- -14854.8%
- EPS (diluted)
- −$1.14
- −14.0% YoY · +52.5% QoQ
Source: XBRL data from the CRISPR Therapeutics AG (CRSP) Q3 2025 10-Q on SEC EDGAR. USD.
CRISPR Therapeutics AG Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: ongoing U.S. government shutdown since Oct 1, 2025 causing FDA, SEC furloughs and layoffs impacting product review timelines
- Updated regulatory risk: potential prolonged delays in FDA's IND submissions and drug approvals due to staffing cuts and disrupted operations
- Impactful compliance risk: federal funding uncertainty for FDA and SEC amid political events risks delayed regulatory approvals affecting commercialization
- Operational risk: interruptions in government agency functions delay regulatory submissions and product development timelines essential for U.S. market entry
- Financial risk: no material changes disclosed, carried-forward risks remain without updates on liquidity, debt maturity, or currency exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CRISPR Therapeutics AG quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.